These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 30041669)

  • 1. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
    Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
    J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal TriCurin, A Synergistic Combination of Curcumin, Epicatechin Gallate and Resveratrol, Repolarizes Tumor-Associated Microglia/Macrophages, and Eliminates Glioblastoma (GBM) and GBM Stem Cells.
    Mukherjee S; Baidoo JNE; Sampat S; Mancuso A; David L; Cohen LS; Zhou S; Banerjee P
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29346317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma.
    Mukherjee S; Baidoo J; Fried A; Atwi D; Dolai S; Boockvar J; Symons M; Ruggieri R; Raja K; Banerjee P
    Int J Cancer; 2016 Dec; 139(12):2838-2849. PubMed ID: 27543754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors.
    Mukherjee S; Hussaini R; White R; Atwi D; Fried A; Sampat S; Piao L; Pan Q; Banerjee P
    Cancer Immunol Immunother; 2018 May; 67(5):761-774. PubMed ID: 29453519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Perspective on Cancer Therapy: Changing the Treaded Path?
    Baidoo JNE; Mukherjee S; Kashfi K; Banerjee P
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
    Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
    J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
    Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
    Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.
    Avril T; Vauleon E; Hamlat A; Saikali S; Etcheverry A; Delmas C; Diabira S; Mosser J; Quillien V
    Brain Pathol; 2012 Mar; 22(2):159-74. PubMed ID: 21790828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.
    Hutter G; Theruvath J; Graef CM; Zhang M; Schoen MK; Manz EM; Bennett ML; Olson A; Azad TD; Sinha R; Chan C; Assad Kahn S; Gholamin S; Wilson C; Grant G; He J; Weissman IL; Mitra SS; Cheshier SH
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):997-1006. PubMed ID: 30602457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
    Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
    Front Immunol; 2021; 12():637053. PubMed ID: 34108959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.
    Szulzewsky F; Pelz A; Feng X; Synowitz M; Markovic D; Langmann T; Holtman IR; Wang X; Eggen BJ; Boddeke HW; Hambardzumyan D; Wolf SA; Kettenmann H
    PLoS One; 2015; 10(2):e0116644. PubMed ID: 25658639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.
    Dumas AA; Pomella N; Rosser G; Guglielmi L; Vinel C; Millner TO; Rees J; Aley N; Sheer D; Wei J; Marisetty A; Heimberger AB; Bowman RL; Brandner S; Joyce JA; Marino S
    EMBO J; 2020 Aug; 39(15):e103790. PubMed ID: 32567735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.
    Morisse MC; Jouannet S; Dominguez-Villar M; Sanson M; Idbaih A
    Expert Rev Neurother; 2018 Sep; 18(9):729-737. PubMed ID: 30099909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis.
    Feng X; Szulzewsky F; Yerevanian A; Chen Z; Heinzmann D; Rasmussen RD; Alvarez-Garcia V; Kim Y; Wang B; Tamagno I; Zhou H; Li X; Kettenmann H; Ransohoff RM; Hambardzumyan D
    Oncotarget; 2015 Jun; 6(17):15077-94. PubMed ID: 25987130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.
    Yin Y; Qiu S; Li X; Huang B; Xu Y; Peng Y
    J Neuroinflammation; 2017 Nov; 14(1):220. PubMed ID: 29132376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
    Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
    Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.